
    
      In this single-centre, open-label, monocenter study, the investigators will enroll 20
      patients with resectable cancer of the stomach of GEJunction.

      All patients will be treated with 1 cycle of atezolizumab monotherapy, followed by 4 cycles
      of combinationtherapy of atezolizumab, capecitabine, oxaliplatin and docetaxel, followed by
      surgery.
    
  